FY2025 · ended Dec 31, 2025 · Revenue $21,796 · Filed Apr 1, 2026
Jupiter Neurosciences, Inc. (JUNS) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $21,796 and a net loss of $8.6 million. As of Jun 30, 2026 it held $1.5 million in cash and investments and $220,607 in total debt.
Revenue
$21,796
Net income (TTM)
$-9.20M
Operating cash flow (TTM)
$-7.25M
Free cash flow
—
EPS (TTM)
$-0.27
Dividend per share
None
Shares outstanding
36.28M
+9.6% vs prior year
Net cash
$1.30M
as of Jun 30, 2026
Operating margin
-40873.2%
FY 2025
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- JUNS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Jupiter, FL
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1679628
- Former names
- Jupiter Orphan Therapeutics, Inc. (until Dec 5, 2017)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
|---|---|---|
| Revenue | $21,796 | — |
| Operating income | -$8.9M | -$3.1M |
| Net income | -$8.6M | -$2.4M |
| Diluted EPS | -$0.25 | -$0.08 |
| Operating cash flow | -$5.4M | -$3.9M |
| Total assets | $5.6M | $6.2M |
| Total liabilities | $7.4M | $2.0M |
| Stockholders' equity | -$1.8M | $4.2M |
| Cash and investments | $3.8M | $3.8M |
| Total debt | $21,247 | $71,329 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Bylaw or fiscal year change
|
Sep 3, 2026 | Aug 28, 2026 |
| 8-K |
Current report
Listing notice, Other events
|
Aug 28, 2026 | Aug 27, 2026 |
| 8-K |
Current report
Material agreement, Officer or director change, Other events
|
Aug 27, 2026 | Aug 26, 2026 |
| 8-K |
Current report
Other events
|
Aug 24, 2026 | Aug 24, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
Aug 24, 2026 | Aug 21, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
All 203 Jupiter Neurosciences, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.